Table of contents

• Autologous Stem Cell Therapy at a Glance
• What Is Autologous Stem Cell Therapy?
• Who Is a Good Candidate for Autologous Stem Cell Therapy?
• What Are the Different Types of Autologous Stem Cell Therapy?
• Why Visit Korea for Autologous Stem Cell Therapy?
• Key Information for International Patients
• Which Are the Best Clinics in Korea for Autologous Stem Cell Therapy?
• Autologous Stem Cell Therapy From Start to Finish
• Alternatives to Autologous Stem Cell Therapy
• How Can I Prepare for Autologous Stem Cell Therapy?
• Aftercare Advice

Considering treatment in Korea? Everything you need to know e.g. — how to avoid scams, visas, interpreters, recovery tips — in our Medical Tourism Master Guide. Plan with confidence in minutes, not weeks!

Last updated: September 2026

Autologous Stem Cell Therapy at a Glance

• Not one standardized procedure — Autologous means the cells come from the recipient, but the term can describe intensive autologous hematopoietic stem-cell transplantation (auto-HSCT) or very different marrow- and fat-derived cell products; diagnosis, cell source, processing, dose, route, and evidence must be confirmed.
• Best candidates — Auto-HSCT is reserved for selected blood cancers, blood disorders, and carefully selected severe autoimmune disease after specialist review of disease status, prior treatment, organ function, infection risk, and ability to complete intensive follow-up.
• Recovery takes weeks to months — After auto-HSCT, high-dose conditioning causes low blood counts and infection risk; engraftment, blood-count recovery, and immune recovery require close monitoring over weeks to months, while non-hematopoietic cell therapies have no universal recovery or results timeline.
• Plan a prolonged Korea stay — Auto-HSCT generally requires several weeks near the transplant center for conditioning, infusion, engraftment, discharge, and fitness-to-fly clearance; return travel can be delayed by fever, infection, unstable blood counts, anemia, or complications.
• No proven repeat or longevity schedule — There is no evidence-based universal timetable for when generic autologous MSC or adipose-cell treatments should work, how long benefits last, or when sessions should be repeated; outcomes should follow the specific protocol’s objective endpoint.
• Key safety limitation — Using a patient’s own cells does not eliminate risks such as anesthesia complications, contamination, infection, thrombosis or embolism, inflammatory reactions, treatment failure, or delayed use of effective standard care.
• Korea requires product-specific verification — Korea’s advanced-regenerative-medicine framework includes designated institutions and national adverse-event and long-term follow-up systems, but this does not validate every clinic claim; obtain the exact product, indication, regulatory pathway, processing facility, and English follow-up plan before paying.

What Is Autologous Stem Cell Therapy?

Autologous stem cell therapy uses cells collected from the same person who receives them, encompassing several distinct treatments rather than one standard procedure. It can restore blood-cell production after intensive treatment for selected diseases or, in other settings, target a specific condition under a defined treatment plan. It ranges from minimally invasive cell collection and injection to intensive surgical or non-surgical transplant-related care, depending on the treatment.

Who Is a Good Candidate for Autologous Stem Cell Therapy?

• Auto-HSCT candidates — People with a selected blood cancer, blood disorder, or carefully selected severe autoimmune disease whose specialist transplant team finds that high-dose conditioning and autologous hematopoietic stem-cell transplantation are appropriate.
• Protocol-specific cell-therapy candidates — People who meet the defined inclusion criteria for a diagnosis-specific Korean clinical-research protocol, reviewed treatment plan, or authorized cell product.
• Patients able to complete follow-up — People with reliable caregiver support where required, access to urgent care, and a written plan for Korean and home-country monitoring.

Autologous means the cells come from the recipient; it does not mean the intervention is proven, low risk, or suitable for wellness use. Auto-HSCT is intensive specialist treatment, and eligibility depends on disease status, previous treatment, performance status, organ reserve, marrow function, infection screening, and ability to tolerate prolonged follow-up. Active or uncontrolled infection, pregnancy, inadequate cardiac, lung, kidney, or liver function, uncontrolled major illness, or inability to provide informed consent can delay or rule out treatment. For marrow-, fat-, or blood-derived stromal-cell products, source-tissue safety, processing feasibility, route of administration, and the exact protocol’s exclusion criteria determine eligibility—not simply whether cells can be collected.

What Are the Different Types of Autologous Stem Cell Therapy?

This umbrella term covers substantially different procedures. Ask for the exact diagnosis, cell source, processing method, product name, dose, route, and regulatory pathway before treating any option as comparable.

• Peripheral-blood auto-HSCT — A growth-factor regimen, commonly including filgrastim, mobilizes blood-forming stem cells into the bloodstream. Cells are collected by leukapheresis, tested, cryopreserved, and reinfused after diagnosis-specific high-dose conditioning; marrow suppression and infection prevention drive recovery.
• Bone-marrow-harvest auto-HSCT — Cells are collected directly from pelvic bone marrow under anesthesia, processed and stored, then reinfused after conditioning. This is a distinct collection approach when peripheral-blood collection is unsuitable or unavailable.
• Marrow-derived MSC or stromal-cell product — Bone-marrow aspirate is processed into a cell preparation, sometimes with culture expansion. Identity, viability, sterility, potency testing, dose, and release criteria are essential details, not technical extras.
• Adipose-derived cell or stromal-cell product — Fat is collected by aspiration or liposuction and processed. “Adipose-derived,” stromal vascular fraction (SVF), and “stem-cell fat” are not interchangeable; the degree of manipulation and intended use affect the risk and regulatory position.
• Route-specific administration — Local, intra-articular, intravenous, intra-arterial, coronary-catheter, intrathecal, and surgical delivery have different hazards and monitoring needs. An MFDS-listed autologous marrow-MSC product has a narrow indication for improving left-ventricular ejection fraction after reperfused acute myocardial infarction and coronary angioplasty; it is not authorization for generic IV, orthopedic, cosmetic, or wellness infusions.

Why Visit Korea for Autologous Stem Cell Therapy?

Korea has a defined advanced-regenerative-medicine framework and national safety-management infrastructure. That is a reason to verify a specific program carefully, not evidence that every advertised autologous cell intervention works. A clinic’s designation or trial listing does not establish that its particular product is approved or appropriate for an individual.

• Designated institutions — Medical institutions must receive Ministry of Health and Welfare designation before conducting advanced-regenerative-medicine clinical research or treatment. MOHW reported 125 designated institutions in April 2025; designation involves requirements for facilities, equipment, personnel, operating procedures, documentary review, and site inspection.
• Treatment-plan oversight — The amended framework, including its treatment-plan pathway, took effect on February 21, 2025. MOHW states that plans can undergo on-site investigation when verification of facilities, personnel, equipment, or human-cell supply arrangements is needed.
• National safety records — Korea’s National Institute of Health is the designated safety-management institution. Its Advanced Regenerative Medicine Information System manages clinical-study and cell-processing records, adverse-event reporting and investigation, institutional reports, and long-term follow-up information.
• Narrow product indications — Korea has product-specific cell-therapy approvals, but they must not be generalized. Confirm the exact indication, rather than accepting claims about anti-aging, fatigue, chronic pain, sexual function, hair loss, or “immune boosting,” for which generic autologous cell-infusion claims lack credible supporting evidence.

Key Information for International Patients

• Minimum stay — Do not market auto-HSCT as a short medical-tourism procedure. Conditioning, infusion, engraftment, discharge, and fitness-to-fly clearance generally require a prolonged stay near the transplant center, often several weeks, with longer local follow-up if complications occur.
• Protocol schedule — A non-hematopoietic cell intervention can require screening, tissue collection, processing, observation, and repeat assessment. Same-day processing and cultured or expanded products have materially different schedules.
• Return flights — Do not buy non-refundable flights until the treating team issues the written protocol schedule and medical clearance. There is no universal “safe to fly after stem cells” interval; infection status, blood counts, anemia, oxygen needs, mobility, thrombosis risk, anesthesia or sedation, and complications determine fitness to travel.
• Repeat visits — No evidence-based universal repeat-session interval exists for generic autologous MSC or adipose-cell injections or infusions. Any repeat treatment must follow the exact protocol and its pre-specified outcome assessment.
• Remote handover — Obtain English discharge documents listing the diagnosis, source tissue, processing method, traceability identifier, dose or cell count where applicable, route, date, medicines, restrictions, adverse events, emergency contact, and follow-up timetable. Arrange handover to a home physician before treatment.

Travel note: After auto-HSCT, fever, unstable blood counts, active infection, uncontrolled symptoms, or a recent readmission can make commercial flying inappropriate without explicit transplant-team clearance.

Which Are the Best Clinics in Korea for Autologous Stem Cell Therapy?

Listed below are some of the best clinics in Korea for autologous stem cell therapy.

1. Cellinique Clinic

You may consider Cellinique Clinic if you are seeking an autologous, blood-based regenerative approach for skin and wellness concerns: its NovaStem treatment uses concentrated autologous blood with the stated aim of supporting aged-cell activation, tissue regeneration, skin elasticity, and health within a personalized treatment plan.

• URL: Cellinique Clinic Website
• Location: Gangnam-gu, Seoul
• Procedure approach:
  • NovaStem uses concentrated autologous blood and is described as a minimally manipulated cell biotechnology.
  • The clinic also describes stem cell therapy for regenerative and metabolic-health goals; the appropriate approach depends on your consultation and individual needs.
• Medical focus:
  • Dr. Chris Gunwoo Kim practices in a one-doctor clinic dedicated to stem cell research.
  • Dr. Kim presented on blood stem cells, tissue regeneration, and the clinic's NovaStem Kit at professional aesthetic-medicine conferences in 2024 and 2025.
• Related options:
  • Complementary options listed include PRP, stem cell fat grafting, exosomes, NK cell therapy, and blood purification.
  • The clinic also provides aesthetic treatments such as Radiesse, Juvelook, thread lifts, injectables, and laser-based skin treatments.

2. SH Clinic

You may consider SH Clinic for autologous stem cell therapy if you want an in-person assessment that can tailor regenerative treatment to a defined concern, including hair loss, knee arthritis, disc disease, autoimmune conditions, sexual health, skin rejuvenation, or wellness and anti-aging goals. Its Wellness & Anti-aging Program is described as drawing on clinical experience to create personalized stem cell plans.

• URL: SH Clinic Website
• Location: Seocho-gu, Seoul
• Autologous treatment examples:
  • For hair loss, the clinic describes injecting autologous stem cells into the scalp to support dormant hair follicles and existing-hair thickness without surgical grafting.
  • For arthritic knees, its BMAC injection delivers concentrated bone-marrow cells to the knee, with the stated aim of addressing inflammation and supporting cartilage repair.
• Conditions and goals:
  • Listed treatment areas include arthritis and disc disease, autoimmune disease, cerebral infarction and dementia, hair loss, skin and cosmetic rejuvenation, and female and male sexual function.
  • The clinic frames its stem cell services within both regenerative-care and wellness/anti-aging programs.
• Consultation and related care:
  • The clinic states that experienced medical staff provide personalized treatment after an in-person consultation and examination.
  • Related services include gynecology, vaginal rejuvenation options, aesthetic dermatology, and hair transplantation.

3. Lydian Plastic Surgery Clinic

You may consider Lydian Plastic Surgery Clinic if you are exploring autologous regenerative treatment or stem-cell-supported fat grafting and want a clinic that can source cells from your own bone marrow, fat, or blood. The clinic states that it is an Advanced Regenerative Medicine Provider with authorized cell-processing facilities, supporting extraction, testing, and processing within its regenerative-treatment system.

• URL: Lydian Plastic Surgery Clinic Website
• Location: Gangnam-gu, Seoul
• Autologous cell sources:
  • The clinic lists bone marrow, fat, and blood as stem cell sources and describes customizing extraction to individual needs.
  • Its stem cell fat grafting combines harvested fat with stem-cell enrichment before reinjection for volume enhancement, including in the face, breasts, or buttocks.
• Regenerative medicine system:
  • The clinic states that its Advanced Regenerative Medicine Provider designation involves Ministry of Health and Welfare approval, personnel and equipment requirements, training, and on-site inspections.
  • It describes a Clean Class 10,000 facility and use of disposable extraction kits as parts of its cell-management and processing system.
• Lead physician and complementary procedures:
  • Dr. An Kyung Chun is listed among the World's Top 100 Doctors in Stem Cell Aesthetic Medicine and is responsible for domestic physician training in high-definition body sculpting and liposuction devices.
  • Related procedures include liposuction, 5D liposculpture, body fat transfer, Brazilian butt lift, full-face fat grafting, and facelift surgery.

Autologous Stem Cell Therapy From Start to Finish

1. Remote screening — Send the diagnosis, pathology, imaging, operative reports, treatment history, recent laboratory results, medication and allergy lists, and home-specialist contact information. Request an English or virtual consultation and a written statement identifying whether the proposal is established care, clinical research, a reviewed treatment plan, or an authorized product.
2. Proposal verification — Before paying a deposit, obtain the exact product name, source tissue, whether cells are minimally manipulated or cultured/expanded, processing facility, dose, route, treatment schedule, Korean authorization or treatment-plan reference, English consent form, adverse-event plan, and compensation arrangements.
3. Specialist assessment and travel coordination — For auto-HSCT, the transplant team reassesses disease status, blood counts, infection risk, heart, lung, kidney, and liver function, and caregiver support. Coordinate flexible accommodation near the center and avoid fixed return flights.
4. Cell collection — Peripheral-blood auto-HSCT generally uses mobilization medication followed by one or more leukapheresis sessions. Bone-marrow collection occurs under anesthesia; marrow- or fat-derived stromal-cell pathways use the defined aspiration or harvest technique.
5. Processing and conditioning — Auto-HSCT cells are counted, tested, cryopreserved, and stored before high-dose conditioning therapy. Other products require route- and product-specific processing and checks at the named cell-processing facility; collection alone does not confirm that a usable product will be released.
6. Administration and observation — Auto-HSCT cells are thawed and infused through a central venous line, followed by frequent blood-count monitoring and supportive care through engraftment. Local injection, IV infusion, catheter delivery, intrathecal administration, and surgical implantation require different observation plans.
7. Discharge and local recovery — Leave only when the responsible team considers discharge appropriate. Auto-HSCT recovery is dominated by cytopenias, infection prevention, transfusion needs, fatigue, nausea, mouth sores, diarrhea, and potential readmission; blood-count and immune recovery continue for weeks to months.
8. Overseas follow-up — Attend the specified laboratory, imaging, and specialist reviews after returning home. Measure outcomes against the protocol’s defined endpoint, such as disease activity, pain and function scores, imaging, or cardiac function—not subjective rejuvenation claims.

Alternatives to Autologous Stem Cell Therapy

The appropriate alternative depends on the diagnosis, not on the broad phrase “stem-cell therapy.” Established medical or surgical care often has a clearer evidence base than an unproven autologous cell intervention; the tradeoff is that these options target a specific disease or anatomical problem rather than promising broad regeneration.

Disease-Specific Stem-Cell Care

• Established transplant pathway — For eligible hematology, oncology, or selected autoimmune cases, specialist evaluation for stem-cell disease therapy distinguishes intensive transplant care from commercial regenerative claims.
• Allogeneic comparison — Donor-cell transplantation can be more appropriate for some diseases, but it introduces donor matching and different immune complications. A transplant specialist must determine whether autologous, allogeneic, or no transplant is indicated.

Orthopedic Care

• Diagnosis-led treatment — Physiotherapy, analgesia, bracing, weight management, evidence-appropriate injections, and orthopedic surgery address the identified cause of pain or dysfunction. A proposed stem-cell injection should never replace a structural diagnosis.
• PRP injection — PRP injection uses platelet-rich plasma and is not another name for stem-cell therapy. Its suitability and evidence also depend on the joint, tendon, injury, and treatment goal.

Aesthetic or Wellness Concerns

• Evidence-based aesthetic care — Dermatologic or plastic-surgery treatments directed at the actual concern are preferable to systemic or unproven cell infusions. Do not substitute stem-cell IV therapy for treatment of a diagnosed disease without product-specific evidence and oversight.
• Condition-specific care — Hair loss, sexual-function concerns, chronic fatigue, and skin aging require diagnosis-led assessment rather than a generic autologous cell product.

How Can I Prepare for Autologous Stem Cell Therapy?

• Document review — Send complete medical records and disclose every prescription medicine, over-the-counter medicine, vitamin, herbal product, hormone, allergy, recreational substance, and prior cell therapy. Include current infection symptoms and vaccination history where relevant.
• Medicine changes — Do not independently stop anticoagulants, antiplatelet drugs, insulin, steroids, seizure medicines, antidepressants, or immunosuppressants. The treating doctor must provide any stop, bridge, or dose-adjustment plan; timing depends on the drug and the collection, anesthesia, catheter, or procedure planned.
• Testing and consent — Complete requested disease reassessment, blood work, infection screening, organ-function testing, imaging, and anesthesia review. Read an English consent form that identifies the exact product, route, expected benefit, known risks, alternatives, and emergency plan.
• Fasting and procedure-site care — Follow the clinic’s fasting instructions for anesthesia, sedation, marrow harvest, catheter placement, or fat harvest. A simple infusion does not automatically require fasting. Follow instructions on bathing, shaving, compression garments, and treatment-area skin preparation.
• Smoking and alcohol — Avoid nicotine, vaping, and alcohol for the timeframe specified by the treating team. These exposures affect anesthesia, respiratory safety, wound healing, infection risk, and medication management.
• Accommodation and companion — Stay near the hospital and arrange a responsible adult for the first night after anesthesia or sedation. Auto-HSCT requires reliable caregiver support and rapid access to the transplant center after discharge.
• Flexible travel — Book changeable accommodation and flights, carry medicines in original labeled containers, and secure travel insurance that does not exclude the planned treatment or complications.

Travel note: Bring translated medical records and establish a home physician willing to receive the Korean discharge summary before departure.

Confirm every clinic-specific fasting, medication, infection-prevention, caregiver, and travel requirement with the treating doctor; individualized instructions take precedence over general guidance.

Aftercare Advice

Follow the written plan for the exact cell product and route of administration; autologous cells do not remove the risks of harvesting, anesthesia, contamination, infection, thrombosis or embolism, inflammatory reactions, or treatment failure.

• Monitoring appointments — Attend all scheduled blood tests, imaging, and clinical reviews. After auto-HSCT, blood-count and immune recovery need ongoing transplant-specialist monitoring for months.
• Medicines and exposure precautions — Take only clinician-approved medicines and supplements. For auto-HSCT, follow the transplant center’s instructions on antimicrobial medicines, food safety, hygiene, vaccinations, and avoiding infectious exposures.
• Line, wound, and harvest-site care — Follow the procedure-specific instructions for central lines, incisions, marrow or fat harvest sites, compression, rehabilitation, weight-bearing, and contact restrictions. Keep dressings and sites clean as directed.
• Activity and travel — Resume activity only according to the team’s restrictions and do not fly without clearance when fever, active infection, low or unstable blood counts, uncontrolled symptoms, reduced oxygen levels, or limited mobility are present.
• Urgent warning signs — Seek urgent medical care for fever or chills, shortness of breath, chest pain, fainting, severe headache, confusion, seizure, new weakness, increasing redness or drainage at a line or procedure site, persistent vomiting or diarrhea, inability to maintain fluids, markedly reduced urination, or rapidly worsening symptoms.

Follow the treating doctor’s instructions over this general guidance, and contact the Korean clinic immediately when anything appears wrong so it can coordinate urgent care and home-country follow-up.